Blood substitute (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Blood substitute" in English language version.

refsWebsite

Global rank English rank

25nih.gov

4^th place

22doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

3web.archive.org

1^st place

2clinicaltrials.gov

5,225^th place

4,062^nd place

2worldcat.org

5^th place

1aana.com

low place

1harvard.edu

18^th place

17^th place

1zenodo.org

621^st place

380^th place

1ems1.com

low place

1nytimes.com

7^th place

1ahajournals.org

3,608^th place

6,526^th place

1bioworld.com

low place

1theglobeandmail.com

293^rd place

203^rd place

1cbc.ca

115^th place

82^nd place

1fiercebiotech.com

low place

8,828^th place

1reuters.com

49^th place

47^th place

1curacyte.eu

low place

1physorg.com

6,156^th place

5,640^th place

1dodlive.mil

7,808^th place

4,539^th place

aana.com

Henkel-Honke, T.; Oleck, M. (2007). "Artificial oxygen carriers: A current review" (PDF). AANA Journal. 75 (3): 205–211. PMID 17591302. Archived from the original (PDF) on 2016-03-04. Retrieved 2016-02-09.

ahajournals.org

circ.ahajournals.org

Wall, T. C.; Califf, R. M.; Blankenship, J.; Talley, J. D.; Tannenbaum, M.; Schwaiger, M.; Gacioch, G.; Cohen, M. D.; Sanz, M.; Leimberger, J. D. (1994). "Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group". Circulation. 90 (1): 114–120. doi:10.1161/01.CIR.90.1.114. PMID 8025985.

bioworld.com

Yoffee, Lynn (May 1, 2008). "Oxycyte is on track as oxygen carrier, not as 'faux' blood". Cardiovascular Device & Drugs. Retrieved 2021-11-28.

cbc.ca

"Hemosol declares insolvency; shares under review by TSX". CBC News. November 25, 2005.

clinicaltrials.gov

"Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI) (STOP-TBI)". 11 November 2014.
"The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (GBM)". 26 February 2019.

curacyte.eu

"Curacyte". Curacyte. Retrieved 30 December 2017.

dodlive.mil

science.dodlive.mil

"Blood Pharming". Armed with Science. Archived from the original on 2019-04-30.

doi.org

Cohn, Claudia S.; Cushing, Melissa M. (2009-04-01). "Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety". Critical Care Clinics. Hemoglobin-based Oxygen Carriers (HBOCs): The Future in Resuscitation?. 25 (2): 399–414. doi:10.1016/j.ccc.2008.12.007. PMID 19341916.
Sarkar, S. (2008). "Artificial Blood". Indian Journal of Critical Care Medicine. 12 (3): 140–144. doi:10.4103/0972-5229.43685. PMC 2738310. PMID 19742251.
Squires JE (2002). "Artificial blood". Science. 295 (5557): 1002–5. Bibcode:2002Sci...295.1002S. doi:10.1126/science.1068443. PMID 11834811. S2CID 35381400.
Boulton, FE (December 2013). "Blood transfusion; additional historical aspects. Part 1. The birth of transfusion immunology". Transfusion Medicine (Oxford, England). 23 (6): 375–81. doi:10.1111/tme.12075. PMID 24003949. S2CID 9038280.
Feigl, EO (January 1983). "Coronary physiology". Physiological Reviews. 63 (1): 1–205. doi:10.1152/physrev.1983.63.1.1. PMID 6296890.
Lahiri, S (April 2000). "Historical perspectives of cellular oxygen sensing and responses to hypoxia". Journal of Applied Physiology. 88 (4): 1467–73. doi:10.1152/jappl.2000.88.4.1467. PMID 10749843. S2CID 18810282.
Reid TJ (2003). "Hb-based oxygen carriers: are we there yet?". Transfusion. 43 (2): 280–7. doi:10.1046/j.1537-2995.2003.00314.x. PMID 12559026. S2CID 21410359.
Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP (1999). "Transfusion medicine. First of two parts--blood transfusion". N. Engl. J. Med. 340 (6): 438–47. doi:10.1056/NEJM199902113400606. PMID 9971869.
Alayash, AI (4 January 2017). "Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?". Biomolecules. 7 (1): 2. doi:10.3390/biom7010002. PMC 5372714. PMID 28054978.
Remy B, Deby-Dupont G, Lamy M (1999). "Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions". Br. Med. Bull. 55 (1): 277–98. doi:10.1258/0007142991902259. PMID 10695091.
Bruno, S.; Ronda, L.; Faggiano, S.; Bettati, S.; Mozzarelli, A. (2010). "Oxygen Delivery via Allosteric Effectors of Hemoglobin and Blood Substitutes". Burger's Medicinal Chemistry and Drug Discovery. doi:10.1002/0471266949.bmc048.pub2. ISBN 978-0471266945.
Wall, T. C.; Califf, R. M.; Blankenship, J.; Talley, J. D.; Tannenbaum, M.; Schwaiger, M.; Gacioch, G.; Cohen, M. D.; Sanz, M.; Leimberger, J. D. (1994). "Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group". Circulation. 90 (1): 114–120. doi:10.1161/01.CIR.90.1.114. PMID 8025985.
Maevsky, E; Ivanitsky, G; Bogdanova, L; Axenova, O; Karmen, N; Zhiburt, E; Senina, R; Pushkin, S; Maslennikov, I; Orlov, A; Marinicheva, I (2005). "Clinical results of Perftoran application: present and future". Artificial Cells, Blood Substitutes, and Biotechnology. 33 (1): 37–46. doi:10.1081/BIO-200046654. PMID 15768564. S2CID 39902507.
Vorob'ev, S. I. (2009-08-19). "First- and second-generation perfluorocarbon emulsions". Pharmaceutical Chemistry Journal. 43 (4): 209–218. doi:10.1007/s11094-009-0268-1. ISSN 0091-150X. S2CID 4890416.
Cohn, Claudia S.; Cushing, Melissa M. (2009). "Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety". Critical Care Clinics. 25 (2): 399–414. doi:10.1016/j.ccc.2008.12.007. PMID 19341916.
Niiler, Eric (2002-10-01). "Setbacks for blood substitute companies". Nature Biotechnology. 20 (10): 962–963. doi:10.1038/nbt1002-962. ISSN 1087-0156. PMID 12355103. S2CID 9147818.
Amberson, William; Jennings J.; Rhode C. (1949). "Clinical Experience with Hemoglobin-Saline Solutions". Journal of Applied Physiology. 1 (7): 469–489. doi:10.1152/jappl.1949.1.7.469. PMID 18104040.
Jiin-Yu Chen; Michelle Scerbo; George Kramer (August 2009). "A Review of Blood Substitutes: Examining The History, Clinical Trial Results, and Ethics of Hemoglobin-Based Oxygen Carriers". Clinics (Sao Paulo). 64 (8): 803–813. doi:10.1590/S1807-59322009000800016. PMC 2728196. PMID 19690667.
Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM (May 2008). "Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis". JAMA. 299 (19): 2304–12. doi:10.1001/jama.299.19.jrv80007. PMC 10802128. PMID 18443023.
Sloan, EP; Koenigsberg, M; Weir, WB; Clark, JM; O'Connor, R; Olinger, M; Cydulka, R (February 2015). "Emergency Resuscitation of Patients Enrolled in the US Diaspirin Cross-linked Hemoglobin (DCLHb) Clinical Efficacy Trial". Prehospital and Disaster Medicine. 30 (1): 54–61. doi:10.1017/S1049023X14001174. PMID 25499006. S2CID 206310955.
Vincent, JL; Privalle, CT; Singer, M; Lorente, JA; Boehm, E; Meier-Hellmann, A; Darius, H; Ferrer, R; Sirvent, JM; Marx, G; DeAngelo, J (January 2015). "Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX)". Critical Care Medicine. 43 (1): 57–64. doi:10.1097/CCM.0000000000000554. PMID 25083980. S2CID 11133338.
Rousseau GF, Giarratana MC, Douay L (Jan 2014). "Large-scale production of red blood cells from stem cells: what are the technical challenges ahead?". Biotechnol. J. 9 (1): 28–38. doi:10.1002/biot.201200368. PMID 24408610. S2CID 28721848.

ems1.com

Webster, Hanna (4 February 2023). "DARPA puts $46.4M toward synthetic blood development". EMS1. Retrieved 2023-02-17.

fiercebiotech.com

"FDA rejects Northfield's blood substitute". FierceBiotech. May 1, 2009.

harvard.edu

ui.adsabs.harvard.edu

Squires JE (2002). "Artificial blood". Science. 295 (5557): 1002–5. Bibcode:2002Sci...295.1002S. doi:10.1126/science.1068443. PMID 11834811. S2CID 35381400.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cohn, Claudia S.; Cushing, Melissa M. (2009-04-01). "Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety". Critical Care Clinics. Hemoglobin-based Oxygen Carriers (HBOCs): The Future in Resuscitation?. 25 (2): 399–414. doi:10.1016/j.ccc.2008.12.007. PMID 19341916.
Henkel-Honke, T.; Oleck, M. (2007). "Artificial oxygen carriers: A current review" (PDF). AANA Journal. 75 (3): 205–211. PMID 17591302. Archived from the original (PDF) on 2016-03-04. Retrieved 2016-02-09.
Sarkar, S. (2008). "Artificial Blood". Indian Journal of Critical Care Medicine. 12 (3): 140–144. doi:10.4103/0972-5229.43685. PMC 2738310. PMID 19742251.
Squires JE (2002). "Artificial blood". Science. 295 (5557): 1002–5. Bibcode:2002Sci...295.1002S. doi:10.1126/science.1068443. PMID 11834811. S2CID 35381400.
Boulton, FE (December 2013). "Blood transfusion; additional historical aspects. Part 1. The birth of transfusion immunology". Transfusion Medicine (Oxford, England). 23 (6): 375–81. doi:10.1111/tme.12075. PMID 24003949. S2CID 9038280.
Feigl, EO (January 1983). "Coronary physiology". Physiological Reviews. 63 (1): 1–205. doi:10.1152/physrev.1983.63.1.1. PMID 6296890.
Lahiri, S (April 2000). "Historical perspectives of cellular oxygen sensing and responses to hypoxia". Journal of Applied Physiology. 88 (4): 1467–73. doi:10.1152/jappl.2000.88.4.1467. PMID 10749843. S2CID 18810282.
Reid TJ (2003). "Hb-based oxygen carriers: are we there yet?". Transfusion. 43 (2): 280–7. doi:10.1046/j.1537-2995.2003.00314.x. PMID 12559026. S2CID 21410359.
Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP (1999). "Transfusion medicine. First of two parts--blood transfusion". N. Engl. J. Med. 340 (6): 438–47. doi:10.1056/NEJM199902113400606. PMID 9971869.
Alayash, AI (4 January 2017). "Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?". Biomolecules. 7 (1): 2. doi:10.3390/biom7010002. PMC 5372714. PMID 28054978.
Remy B, Deby-Dupont G, Lamy M (1999). "Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions". Br. Med. Bull. 55 (1): 277–98. doi:10.1258/0007142991902259. PMID 10695091.
Wall, T. C.; Califf, R. M.; Blankenship, J.; Talley, J. D.; Tannenbaum, M.; Schwaiger, M.; Gacioch, G.; Cohen, M. D.; Sanz, M.; Leimberger, J. D. (1994). "Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group". Circulation. 90 (1): 114–120. doi:10.1161/01.CIR.90.1.114. PMID 8025985.
Maevsky, E; Ivanitsky, G; Bogdanova, L; Axenova, O; Karmen, N; Zhiburt, E; Senina, R; Pushkin, S; Maslennikov, I; Orlov, A; Marinicheva, I (2005). "Clinical results of Perftoran application: present and future". Artificial Cells, Blood Substitutes, and Biotechnology. 33 (1): 37–46. doi:10.1081/BIO-200046654. PMID 15768564. S2CID 39902507.
Cohn, Claudia S.; Cushing, Melissa M. (2009). "Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety". Critical Care Clinics. 25 (2): 399–414. doi:10.1016/j.ccc.2008.12.007. PMID 19341916.
Niiler, Eric (2002-10-01). "Setbacks for blood substitute companies". Nature Biotechnology. 20 (10): 962–963. doi:10.1038/nbt1002-962. ISSN 1087-0156. PMID 12355103. S2CID 9147818.
Amberson, William; Jennings J.; Rhode C. (1949). "Clinical Experience with Hemoglobin-Saline Solutions". Journal of Applied Physiology. 1 (7): 469–489. doi:10.1152/jappl.1949.1.7.469. PMID 18104040.
Jiin-Yu Chen; Michelle Scerbo; George Kramer (August 2009). "A Review of Blood Substitutes: Examining The History, Clinical Trial Results, and Ethics of Hemoglobin-Based Oxygen Carriers". Clinics (Sao Paulo). 64 (8): 803–813. doi:10.1590/S1807-59322009000800016. PMC 2728196. PMID 19690667.
Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM (May 2008). "Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis". JAMA. 299 (19): 2304–12. doi:10.1001/jama.299.19.jrv80007. PMC 10802128. PMID 18443023.
Sloan, EP; Koenigsberg, M; Weir, WB; Clark, JM; O'Connor, R; Olinger, M; Cydulka, R (February 2015). "Emergency Resuscitation of Patients Enrolled in the US Diaspirin Cross-linked Hemoglobin (DCLHb) Clinical Efficacy Trial". Prehospital and Disaster Medicine. 30 (1): 54–61. doi:10.1017/S1049023X14001174. PMID 25499006. S2CID 206310955.
Vincent, JL; Privalle, CT; Singer, M; Lorente, JA; Boehm, E; Meier-Hellmann, A; Darius, H; Ferrer, R; Sirvent, JM; Marx, G; DeAngelo, J (January 2015). "Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX)". Critical Care Medicine. 43 (1): 57–64. doi:10.1097/CCM.0000000000000554. PMID 25083980. S2CID 11133338.
Rousseau GF, Giarratana MC, Douay L (Jan 2014). "Large-scale production of red blood cells from stem cells: what are the technical challenges ahead?". Biotechnol. J. 9 (1): 28–38. doi:10.1002/biot.201200368. PMID 24408610. S2CID 28721848.

ncbi.nlm.nih.gov

Sarkar, S. (2008). "Artificial Blood". Indian Journal of Critical Care Medicine. 12 (3): 140–144. doi:10.4103/0972-5229.43685. PMC 2738310. PMID 19742251.
Alayash, AI (4 January 2017). "Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?". Biomolecules. 7 (1): 2. doi:10.3390/biom7010002. PMC 5372714. PMID 28054978.
Jiin-Yu Chen; Michelle Scerbo; George Kramer (August 2009). "A Review of Blood Substitutes: Examining The History, Clinical Trial Results, and Ethics of Hemoglobin-Based Oxygen Carriers". Clinics (Sao Paulo). 64 (8): 803–813. doi:10.1590/S1807-59322009000800016. PMC 2728196. PMID 19690667.
Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM (May 2008). "Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis". JAMA. 299 (19): 2304–12. doi:10.1001/jama.299.19.jrv80007. PMC 10802128. PMID 18443023.

nytimes.com

"Artificial Blood Given to Jehovah's Witness in First American Use". The New York Times. 21 November 1979.

physorg.com

Edwards, L. (July 13, 2010). Artificial blood developed for the battlefield. Retrieved November 30, 2010

reuters.com

"Northfield Laboratories to liquidate under Chapter 11". Reuters. 2 June 2009. Retrieved 2017-12-31.

semanticscholar.org

api.semanticscholar.org

Squires JE (2002). "Artificial blood". Science. 295 (5557): 1002–5. Bibcode:2002Sci...295.1002S. doi:10.1126/science.1068443. PMID 11834811. S2CID 35381400.
Boulton, FE (December 2013). "Blood transfusion; additional historical aspects. Part 1. The birth of transfusion immunology". Transfusion Medicine (Oxford, England). 23 (6): 375–81. doi:10.1111/tme.12075. PMID 24003949. S2CID 9038280.
Lahiri, S (April 2000). "Historical perspectives of cellular oxygen sensing and responses to hypoxia". Journal of Applied Physiology. 88 (4): 1467–73. doi:10.1152/jappl.2000.88.4.1467. PMID 10749843. S2CID 18810282.
Reid TJ (2003). "Hb-based oxygen carriers: are we there yet?". Transfusion. 43 (2): 280–7. doi:10.1046/j.1537-2995.2003.00314.x. PMID 12559026. S2CID 21410359.
Maevsky, E; Ivanitsky, G; Bogdanova, L; Axenova, O; Karmen, N; Zhiburt, E; Senina, R; Pushkin, S; Maslennikov, I; Orlov, A; Marinicheva, I (2005). "Clinical results of Perftoran application: present and future". Artificial Cells, Blood Substitutes, and Biotechnology. 33 (1): 37–46. doi:10.1081/BIO-200046654. PMID 15768564. S2CID 39902507.
Vorob'ev, S. I. (2009-08-19). "First- and second-generation perfluorocarbon emulsions". Pharmaceutical Chemistry Journal. 43 (4): 209–218. doi:10.1007/s11094-009-0268-1. ISSN 0091-150X. S2CID 4890416.
Niiler, Eric (2002-10-01). "Setbacks for blood substitute companies". Nature Biotechnology. 20 (10): 962–963. doi:10.1038/nbt1002-962. ISSN 1087-0156. PMID 12355103. S2CID 9147818.
Sloan, EP; Koenigsberg, M; Weir, WB; Clark, JM; O'Connor, R; Olinger, M; Cydulka, R (February 2015). "Emergency Resuscitation of Patients Enrolled in the US Diaspirin Cross-linked Hemoglobin (DCLHb) Clinical Efficacy Trial". Prehospital and Disaster Medicine. 30 (1): 54–61. doi:10.1017/S1049023X14001174. PMID 25499006. S2CID 206310955.
Vincent, JL; Privalle, CT; Singer, M; Lorente, JA; Boehm, E; Meier-Hellmann, A; Darius, H; Ferrer, R; Sirvent, JM; Marx, G; DeAngelo, J (January 2015). "Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX)". Critical Care Medicine. 43 (1): 57–64. doi:10.1097/CCM.0000000000000554. PMID 25083980. S2CID 11133338.
Rousseau GF, Giarratana MC, Douay L (Jan 2014). "Large-scale production of red blood cells from stem cells: what are the technical challenges ahead?". Biotechnol. J. 9 (1): 28–38. doi:10.1002/biot.201200368. PMID 24408610. S2CID 28721848.

theglobeandmail.com

Zehr, Leonard (June 21, 2003). "Tests leave Hemosol in critical condition". Globe and Mail.

web.archive.org

Henkel-Honke, T.; Oleck, M. (2007). "Artificial oxygen carriers: A current review" (PDF). AANA Journal. 75 (3): 205–211. PMID 17591302. Archived from the original (PDF) on 2016-03-04. Retrieved 2016-02-09.
Biopure files for relief PR Newswire, July 16, 2009.
"Blood Pharming". Armed with Science. Archived from the original on 2019-04-30.

worldcat.org

search.worldcat.org

Vorob'ev, S. I. (2009-08-19). "First- and second-generation perfluorocarbon emulsions". Pharmaceutical Chemistry Journal. 43 (4): 209–218. doi:10.1007/s11094-009-0268-1. ISSN 0091-150X. S2CID 4890416.
Niiler, Eric (2002-10-01). "Setbacks for blood substitute companies". Nature Biotechnology. 20 (10): 962–963. doi:10.1038/nbt1002-962. ISSN 1087-0156. PMID 12355103. S2CID 9147818.

zenodo.org

Reid TJ (2003). "Hb-based oxygen carriers: are we there yet?". Transfusion. 43 (2): 280–7. doi:10.1046/j.1537-2995.2003.00314.x. PMID 12559026. S2CID 21410359.